Trial · NCT06594939
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
NCT06594939, Phase 2, Recruiting, Medical College of Wisconsin
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma. Trials, record NCT06594939. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06594939
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
- NCT number
- NCT06594939
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 31 participants, estimated
- Lead sponsor
- Medical College of Wisconsin
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide, Doxorubicin, Prednisone, Pegfilgrastim
- First posted
- 2024-09-19
- Last updated
- 2026-08-25
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response | Up to six months. | This is defined as the number of subjects achieving a complete response at the end of treatment using the Lugano criteria. |
| Secondary | Partial Response | Up to six months | This is defined as the number of subjects achieving a partial response at the end of treatment using the Lugano criteria. |
| Secondary | Duration of Response | Up to 60 months | This is defined as the time from the first documentation of tumor response to disease progression (per the Lugano criteria), relapse, or death among patients who achieve a response of partial response or better. The measure will be the median duration of response in months. |
| Secondary | Overall Survival | 2 years | This outcome measure is the number of subjects expiring from any cause. |
| Secondary | Adverse Events | Up to 7 months | The number of grade 3 or higher adverse events possibly, probably, or definitely related to study therapy in the safety run-in population from the start of therapy through 30 days after the end of study therapy. Adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, version 5.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded using the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system described by Lee et al., 2019. The scale for ICANS will be the ASTCT ICANS consensus grading for adults. The score evaluates neurotoxicity domains. The lowest grade is 1 (less severe) and the highest is 4 (more severe). The ASTCT Consensus Grading for CRS, is based on the severity of the patient's symptoms. The lowest grade is 1 and the highest is 4. The higher the grade, the more severe. |
| Secondary | Study therapy completion | Up to 6 months | The number of subjects who complete the study therapy. |
| Secondary | Eligibility for abbreviated therapy | 56 days | The number of subjects eligible for abbreviated therapy. |
| Secondary | Eligibility for full therapy | 56 days | The number of subjects eligible for full therapy. |
| Secondary | CRS or ICANS | 28 days | The number of subjects experiencing a CRS or ICANS of the total study population within the first 28 days after study therapy start. The scale for ICANS will be the ASTCT ICANS consensus grading for adults. The score evaluates various neurotoxicity domains. The lowest grade is 1 and the highest is 4. The higher the grade, the more severe the symptoms. The scale for CRS, ASTCT Consensus Grading for CRS, is based on the severity of the patient's symptoms. The lowest grade is 1 and the highest is 4. The higher the grade, the more severe the symptoms. |
| Secondary | Minimal residual disease at Cycle 3 | 56 days | The number of subjects who achieve minimal residual disease negativity at Cycle 3. This will be determined using the clonoSEQ assay. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06594939
GET https://conductscience.org/api/trials/v1/NCT06594939/registered